Jesper Hoiland Acquires 6,800 Shares of Radius Health, Inc. (RDUS) Stock
Radius Health, Inc. (NASDAQ:RDUS) insider Jesper Hoiland acquired 6,800 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average cost of $29.04 per share, with a total value of $197,472.00. Following the transaction, the insider now directly owns 12,900 shares in the company, valued at approximately $374,616. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jesper Hoiland also recently made the following trade(s):
- On Friday, September 15th, Jesper Hoiland acquired 6,100 shares of Radius Health stock. The shares were acquired at an average cost of $32.72 per share, with a total value of $199,592.00.
Radius Health, Inc. (RDUS) opened at $28.75 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health, Inc. has a 1-year low of $27.16 and a 1-year high of $55.97.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm earned ($1.07) EPS. equities research analysts anticipate that Radius Health, Inc. will post -5.41 EPS for the current fiscal year.
Several large investors have recently modified their holdings of RDUS. BlackRock Inc. boosted its holdings in shares of Radius Health by 98,245.6% during the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after acquiring an additional 2,628,070 shares during the period. Farallon Capital Management LLC raised its position in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after buying an additional 569,300 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in shares of Radius Health in the second quarter valued at approximately $25,589,000. BB Biotech AG raised its position in shares of Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after buying an additional 498,400 shares in the last quarter. Finally, RA Capital Management LLC acquired a new stake in shares of Radius Health in the second quarter valued at approximately $22,486,000.
RDUS has been the subject of several recent research reports. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the stock a “buy” rating in a report on Sunday, July 23rd. BidaskClub cut Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Jefferies Group LLC restated a “hold” rating and set a $38.00 price target (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $51.00.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.